News

Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has…
Read More...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47…
Read More...

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is…
Read More...

Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Lonza announced a strategic collaboration…
Read More...

CuraSen Therapeutics, Inc., a privately held clinical-stage biotechnology company, announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032,…
Read More...

Novus Therapeutics, Inc. announced it has completed the acquisition of Anelixis Therapeutics, Inc. a privately held clinical stage biotechnology company developing a next generation…
Read More...

BioNTech SE announced that it will receive a grant of up to 375 million Euro from an initiative by the German Federal Ministry of Education and Research (BMBF) to support the…
Read More...

Axovant Gene Therapies Ltd announced that it has signed a strategic partnership with Viralgen, a leading Contract Development and Manufacturing Organization (CDMO). Leveraging the…
Read More...

Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in…
Read More...

HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company focused on the development of novel antibodies in immunomodulation, announced a partnership agreement with…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3…
Read More...

Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and…
Read More...

Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, and Dynavax Technologies Corporation, a biopharmaceutical company focused on developing…
Read More...

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs,  announced a vaccine partnership with the UK government for its inactivated…
Read More...

Ansa Biotechnologies announced that it has raised $7.9 million in an oversubscribed Seed round of funding led by Horizons Ventures, with participation from Mubadala Capital, Humboldt…
Read More...

Pfizer Inc. and BioNTech SE announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19…
Read More...

Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced a strategic partnership agreement with Hualan Genetic Engineering Co., Ltd (Hualan…
Read More...

Boehringer Ingelheim and Click Therapeutics announced they have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic. It…
Read More...

Global contract packaging organisation (CPO), Tjoapack is investing in its automated packaging capabilities to meet growing customer demand for pre-filled syringes and vials. The new…
Read More...

Integral Molecular announces the development of Humanized Chicken Antibody Technology (hCAT) and the incorporation of hCAT into the company's industry-leading MPS antibody discovery…
Read More...